Dicot

Today, Dicot submitted a patent application to the United States Patent and Trademark Office. It concerns patenting a method of formulating LIB-01 that enables an oral intake of the active substance. The new oral formulation was developed in 2022 and is now being used in the company's clinical phase 1 study.

Dicot announced last year that the company had submitted a new patent application covering new production methods and chemical compounds. Now Dicot is converting yet another of the company's trade secrets into a patent. The application is a so-called provisional patent application that aims to get an approved patent in the United States. Shortly, this will be followed by an application to the Swedish Patent and Registration Office where the application can later be expanded to other markets.

"The ambition is to continue to reinforce and globalize our patent portfolio and we are working very actively with this. With new patents that provide market exclusivity for 20 years, we will strengthen our position and the value of LIB-01 further for a very long time", comments Elin Trampe, CEO at Dicot.

For further information, please contact:

Elin Trampe, CEO
Phone: +46 72 502 10 10
E-mail: elin.trampe@dicot.se

About Dicot AB

Dicot is developing the drug candidate LIB-01, which will be a potency agent to better treat erectile dysfunction and premature ejaculation. The ambition is to create a drug with significantly longer effect and far fewer side effects, compared to current available drugs. Today, over 500 million men suffer from these sexual dysfunctions and the market is valued at USD 8 billion. Dicot's strategy is to develop LIB-01 under own auspices until phase 2a studies and thereafter in partnership with larger, established pharmaceutical companies, finance and develop LIB-01 further to a registered pharmaceutical on the world market.

Dicot is listed on Spotlight Stock Market and has approximately 4,400 shareholders. For more information, please visit www.dicot.se.